Spots Global Cancer Trial Database for Abemaciclib (LY2835219) in Patients With Recurrent Primary Brain Tumors
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Abemaciclib (LY2835219) in Patients With Recurrent Primary Brain Tumors
Official Title: A Phase 2 Study of Abemaciclib in Patients With Recurrent Primary Brain Tumors
Study ID: NCT03220646
Conditions
Study Description
Brief Summary: The purpose of this study is to test any good and bad effects of a study drug called abemaciclib (LY2835219) in patients with recurrent brain tumors.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Hartford Healthcare Cancer Institute @ Hartford Hospital (Data collection only), Hartford, Connecticut, United States
Memorial Sloan Kettering Basking Ridge (All Protocol Activities), Basking Ridge, New Jersey, United States
Memorial Sloan Kettering Monmouth (All Protocol Activities), Middletown, New Jersey, United States
Memorial Sloan Kettering Bergen (All Protocol Activities), Montvale, New Jersey, United States
Memorial Sloan Kettering Commack (All Protocol Activities), Commack, New York, United States
Memorial Sloan Kettering Westchester (All Protocol Activities), Harrison, New York, United States
Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York, United States
Lehigh Valley Health Network, Allentown, Pennsylvania, United States
Contact Details
Name: Thomas Kaley, MD
Affiliation: Memorial Sloan Kettering Cancer Center
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
